Cibus Past Earnings Performance

Past criteria checks 0/6

Cibus's earnings have been declining at an average annual rate of -38.6%, while the Biotechs industry saw earnings growing at 14.7% annually. Revenues have been declining at an average rate of 12.1% per year.

Key information

-38.6%

Earnings growth rate

26.4%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	-12.1%
Return on equity	-112.3%
Net Margin	-12,313.3%
Last Earnings Update	31 Mar 2024

Recent past performance updates

Recent updates

Calyxt signs agreement with Evologic to scale production of plant-based ingredients

Oct 07

Calyxt exploring strategic alternatives

Sep 22

Calyxt Switches Gears Again, But The Cash Clock Keeps Ticking Down

Apr 01

Calyxt Needs To Secure More Commercial Partners As Cash Dwindles

Sep 16

Will Calyxt (NASDAQ:CLXT) Spend Its Cash Wisely?

Aug 17

Analysts Just Shaved Their Calyxt, Inc. (NASDAQ:CLXT) Forecasts Dramatically

May 11

Calyxt, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 08

Is Calyxt (NASDAQ:CLXT) A Risky Investment?

Apr 30

Calyxt, Inc. (NASDAQ:CLXT) Analysts Just Cut Their EPS Forecasts Substantially

Mar 09

Here's What Calyxt, Inc.'s (NASDAQ:CLXT) Shareholder Ownership Structure Looks Like

Feb 25

Revenue & Expenses Breakdown
Beta

How Cibus makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:CBUS Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Mar 24	2	-286	21	45
31 Dec 23	2	-268	16	36
30 Sep 23	1	-53	13	25
30 Jun 23	0	-33	11	14
31 Mar 23	0	-17	10	11
31 Dec 22	0	-17	11	12
30 Sep 22	2	-21	14	12
30 Jun 22	10	-22	14	12
31 Mar 22	22	-25	14	11
31 Dec 21	26	-29	15	11
30 Sep 21	38	-36	16	12
30 Jun 21	35	-38	17	11
31 Mar 21	26	-44	19	11
31 Dec 20	24	-45	21	11
30 Sep 20	14	-44	23	11
30 Jun 20	11	-45	25	12
31 Mar 20	10	-43	26	12
31 Dec 19	7	-40	25	12
30 Sep 19	4	-36	25	11
30 Jun 19	1	-33	23	11
31 Mar 19	0	-31	20	12
31 Dec 18	0	-28	18	10
30 Sep 18	0	-26	16	10
30 Jun 18	0	-32	19	13
31 Mar 18	0	-28	16	11
31 Dec 17	1	-26	15	12
30 Sep 17	0	-24	13	11
30 Jun 17	0	-13	8	6
31 Mar 17	0	-12	7	6
31 Dec 16	0	-12	7	6
31 Dec 15	1	-6	4	3

Quality Earnings: CBUS is currently unprofitable.

Growing Profit Margin: CBUS is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: CBUS is unprofitable, and losses have increased over the past 5 years at a rate of 38.6% per year.

Accelerating Growth: Unable to compare CBUS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CBUS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).

Return on Equity

High ROE: CBUS has a negative Return on Equity (-112.32%), as it is currently unprofitable.

Cibus Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Full year 2023 earnings released: US$25.95 loss per share (vs US$18.36 loss in FY 2022)

Cibus, Inc. to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Recent updates

Full year 2023 earnings released: US$25.95 loss per share (vs US$18.36 loss in FY 2022)

Consensus revenue estimates increase by 18%

Cibus, Inc. Appoints Jason Stokes as Chief Legal Officer, General Counsel and Corporate Secretary

Cibus, Inc. to Report Q1, 2024 Results on May 09, 2024

Cibus, Inc., Annual General Meeting, May 30, 2024

Consensus EPS estimates upgraded to US$3.03 loss, revenue downgraded

Consensus EPS estimates fall by 21%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Cibus 2023 Field Trial Results Move Developed Traits Closer to Product Sales

Cibus: Expanding Opportunities And Growing Accessible Market

Cibus, Inc. Announces Successfully Regenerated Plants from Single Cells in Wheat

Cibus, Inc. has filed a Follow-on Equity Offering in the amount of $80 million.

Co-Founder recently bought US$5.5m worth of stock

Cibus, Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates increase by 15%, EPS downgraded

Price target decreased by 13% to US$22.00

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Cibus, Inc. Announces Resignation of Jim Collins as Member of Board of Directors and Member of Nominating and Corporate Governance Committee

Is Cibus, Inc. (NASDAQ:CBUS) Trading At A 44% Discount?

Cibus, Inc. Appoints Jim Collins to Board of Directors

Does Cibus (NASDAQ:CBUS) Have A Healthy Balance Sheet?

Consensus revenue estimates fall by 60%

Second quarter 2023 earnings released: US$3.05 loss per share (vs US$2.66 loss in 2Q 2022)

Cibus, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Price target decreased by 50% to US$18.00

Consensus revenue estimates increase by 46%

New major risk - Shareholder dilution

First quarter 2023 earnings released: US$1.09 loss per share (vs US$1.34 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Calyxt, Inc. Achieves Phase 1 Milestone in Collaboration Agreement to Develop Alternative to Palm Oil

Calyxt Gets 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

High number of new directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.20 loss in 3Q 2021)

Calyxt, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Calyxt, Inc Produces Plant-Based Squalene, an Important Ingredient in Personal Care Products and Critical Vaccine Adjuvants

Calyxt signs agreement with Evologic to scale production of plant-based ingredients

Calyxt exploring strategic alternatives

Consensus forecasts updated

Forecast to breakeven in 2024

Second quarter 2022 earnings released: US$0.053 loss per share (vs US$0.13 loss in 2Q 2021)

Price target increased to US$6.83

Calyxt, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Calyxt Receives Non-Compliance Notice from Nasdaq

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$4.99

High number of new directors

Calyxt, Inc. Announces Directorate Appointments

Calyxt, Inc. to Report Q1, 2022 Results on May 05, 2022

Calyxt, Inc., Annual General Meeting, Jun 01, 2022

Calyxt Switches Gears Again, But The Cash Clock Keeps Ticking Down

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Calyxt, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Price target increased to US$8.67

Third quarter 2021 earnings released: US$0.20 loss per share (vs US$0.28 loss in 3Q 2020)

Calyxt Needs To Secure More Commercial Partners As Cash Dwindles

Chief Financial Officer recently bought US$64k worth of stock

Will Calyxt (NASDAQ:CLXT) Spend Its Cash Wisely?

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.33 loss in 2Q 2020)

Calyxt, Inc.(NasdaqGM:CLXT) dropped from Russell Microcap Value Index

No longer forecast to breakeven

Independent Director recently bought US$59k worth of stock

Consensus revenue estimates fall to US$23.2m

Analysts Just Shaved Their Calyxt, Inc. (NASDAQ:CLXT) Forecasts Dramatically

Price target decreased to US$7.63

Revenue & Expenses Breakdown
Beta